Current Screening and Surveillance Guidelines for Colorectal Cancer and Polyps

Participants will review the most updated screening and surveillance guidelines to determine when to start screening their patients for colorectal cancer and when follow up procedures are indicated.

Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 10/21/2020 and they are subject to change as new information is published.

Target Audience

For APRNs and PAs, AANPCB and NCCPA accept AMA PRA Category 1 Credit™ as the number of hours of participation (AANPCB) or as Category 1 CME credits (NCCPA).

Learning Objectives

  • Review screening and surveillance guidelines for colorectal cancer
  • Discuss indications for follow up procedures 

Additional Information

Partner: 
Pri-Med
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit
  • 0.50 Attendance
Course opens: 
10/21/2020
Course expires: 
10/21/2021
Rating: 
0

Jennifer A. Bierman, MD, FACP

Associate Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL

Christian G. Stevoff, MD

Clinical Practice Director
Division of Gastroenterology
Northwestern Medicine
Chicago, IL

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email [email protected] or call (877) 477-4633.

AMA PRA Category 1 Credits

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For APRNs and PAs, AANPCB and NCCPA accept AMA PRA Category 1 Credit™ as the number of hours of participation (AANPCB) or as Category 1 CME credits (NCCPA).

 

Available Credit

  • 0.50 AMA PRA Category 1 Credit
  • 0.50 Attendance
Please login or register to take this course.

This course is offered through Pri-Med. To take this course you will be redirected to Pri-Med's website. You must have an account with Pri-Med in order to complete this activity. 

Mocingbird continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!